Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Oncy save search
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 6.52%
H: 6.12%
C: 5.1%
biotech cancer pancreatic
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
Published: 2023-10-23 (Crawled : 11:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.65%
H: 9.94%
C: 8.33%
success cancer study
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
Published: 2023-10-23 (Crawled : 11:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.65%
H: 9.94%
C: 8.33%
positive cancer pancreatic study
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
Published: 2023-10-20 (Crawled : 14:30) - prnewswire.com
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.85%
H: 3.14%
C: -2.52%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.41%
H: 3.13%
C: 2.38%
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: 0.02%
H: 0.94%
C: -0.3%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.46%
H: 0.48%
C: -1.06%
companies biotech cancer pancreatic treatment research
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Published: 2023-10-13 (Crawled : 13:00) - prnewswire.com
PYXS | $4.155 -8.28% -9.03% 670K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 2.56%
C: 2.56%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.63%
H: 4.97%
C: 2.76%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 0.47%
H: 1.7%
C: -0.38%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
fda year review cancer pancreatic
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Published: 2023-09-26 (Crawled : 11:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 5.63%
C: 4.69%
biotech award cancer pancreatic network
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.72 0.27% 0.27% 76K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.41%
H: 0.68%
C: 0.64%
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -4.55%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.63%
H: 1.87%
C: -1.25%
ITOS | $10.58 2.42% 2.36% 940K
|
Health Technology
|
| O: -0.52%
H: 3.23%
C: -2.2%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.42%
H: 3.56%
C: 3.48%
cancer
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
Published: 2023-06-05 (Crawled : 11:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.74%
H: 2.96%
C: -2.96%
biotech breast cancer trial response show
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Published: 2023-05-31 (Crawled : 16:00) - biospace.com/
INAB | $1.0 -4.76% -5.0% 280K
|
|
| O: 0.35%
H: 6.57%
C: 5.19%
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: -0.43%
H: 3.05%
C: 1.21%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.81%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.09%
H: 2.57%
C: 1.13%
GERN | $3.69 -1.07% -1.08% 8.2M
|
Health Technology
|
| O: 0.6%
H: 2.1%
C: -2.1%
asco cancer meeting set
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
Published: 2023-05-25 (Crawled : 22:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -18.22%
biotech breast asco positive cancer meeting trial
Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 00:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.88%
H: 15.18%
C: 13.39%
biotech breast presentation asco cancer meeting trial
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
Published: 2023-03-24 (Crawled : 13:20) - prnewswire.com
RLAY | $5.96 -2.46% -2.52% 2.4M
|
Health Technology
|
| O: -0.71%
H: 0.72%
C: -0.39%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: -3.2%
HOLX | $75.37 0.36% 0.36% 1.3M
|
Health Technology
|
| O: -0.04%
H: 1.03%
C: 0.89%
CTMX | $1.67 -3.47% -3.59% 510K
|
Health Technology
|
| O: 0.59%
H: 1.76%
C: 0.0%
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: -0.58%
H: 2.65%
C: 2.06%
breast hope cancer
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
Published: 2022-12-01 (Crawled : 13:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.11%
H: 23.24%
C: 14.59%
biotech treatment fda designation cancer pancreatic fast track designation
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
Published: 2022-11-21 (Crawled : 15:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 3.57%
C: -3.93%
biotech breast symposium cancer
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
Published: 2022-11-14 (Crawled : 16:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.92%
H: 0.48%
C: -0.84%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.83%
H: 1.63%
C: -0.26%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 3.64%
H: 0.58%
C: -7.6%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.61%
H: 6.39%
C: 5.49%
biotech cancer pancreatic
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Published: 2022-11-10 (Crawled : 14:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.06%
H: 6.42%
C: 4.81%
biotech meeting response cancer pancreatic
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
Published: 2022-11-07 (Crawled : 13:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 9.52%
H: 10.87%
C: 8.7%
biotech meeting response results cancer study pancreatic phase 1
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.77%
H: 0.76%
C: -3.05%
biotech immunotherapy meeting cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.